secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0000010795-24-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q1 revenue $4.7B (+2.6% YoY), GAAP EPS $0.96, adj. EPS $2.68; raises FY2024 guide
--------------------------------------------------------------------------------

- Q1 revenue $4,706M, up 2.6% as reported, 2.4% organic; currency-neutral growth 1.6%.
- GAAP diluted EPS $0.96 vs. $1.70 prior year; adjusted diluted EPS $2.68 vs. $2.98.
- Company raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidance.
- BD Medical launched SiteRite 9 Ultrasound System; BD Life Sciences received FDA clearance for MiniDraw Capillary Blood Collection System.
- BD signed World Economic Forum's Zero Health Gaps Pledge, reinforcing health equity commitment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000015/0000010795-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000015/bdx-20240201.htm
  HTML page:      https://secwatch.observer/filing/0000010795-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer